Ardelyx, Inc., founded in Fremont, United States, is a biotechnology company dedicated to developing innovative drugs that address significant unmet medical needs in metabolic disorders. The company's core mission is to advance patient care by targeting specific transporters, channels, and receptors in the gastrointestinal tract to correct mineral metabolism imbalances. Ardelyx offers a range of first-in-class therapies designed to modulate these functions, focusing on conditions such as hyperphosphatemia and irritable bowel syndrome.

Notable figures affiliated with Ardelyx include its experienced leadership team and board members who have extensive backgrounds in biotechnology and pharmaceuticals. The company has attracted significant investment from leading venture capital firms and strategic partners. Ardelyx's key achievements include the development and FDA approval of its flagship products, which have had a substantial impact on improving patient outcomes. Through its pioneering science and commitment to making a difference, Ardelyx continues to influence the biotech industry positively.